Clinical and pathological features of BRCA1/2 tumors in a sample of high-risk Moroccan breast cancer patients. (December 2016)

• Record Type: Journal Article
• Authors: Jouhadi, Hassan; Tazzite, Amal; Azeddoug, Houssine; Naim, Asmâa; Nadifi, Sellama; Benider, Abdellatif
• Is Part Of: BMC research notes. Volume 9:Number 1(2016)
• Page Start: 1
• Page End: 7
• Publication Date: 2016-12
• Subjects: Breast cancer -- BRCA1 -- BRCA2 -- Clinicopathological -- Characteristics -- Morocco; Medicine -- Periodicals; Biology -- Periodicals; 610.5
• DOI: 10.1186/s13104-016-2057-8
• Languages: English
• ISSNs: 1756-0500

Abstract

Abstract Background BRCA1 andBRCA2 genes explain a large part of hereditary breast cancer. Several studies have shown thatBRCA1 andBRCA2 tumors exhibit some specific morphological and immunohistochemical characteristics. The aim of our study is to compare the clinicopathological characteristics between Moroccan breast cancers associated or not withBRCA1 andBRCA2 mutations. Previously, we had identified 11BRCA carriers in a series of 40 selected breast cancer patients at increased risk for carrying a mutation in theBRCA1 andBRCA2 genes. The clinical and pathological features of patients carryingBRCA1 orBRCA2 mutation (n = 11) were evaluated and compared to those of non-mutated patients (n = 29). Results In comparison with non carriers, women withBRCA1 /2 mutation present younger mean age at diagnosis (37.90 vs. 44.48 years, p = 0.05), younger mean age of 1st menarche (13.08 vs. 14.24 years, p = 0.05) and shorter duration of breastfeeding (8.71 vs. 19.35 months, p = 0.05). Moreover, 63.6 and 62.5 % ofBRCA1 /2 carriers present SBR grade III and triple negative tumors respectively (p = 0.02). Conclusions In this first Moroccan study comparing clinical and pathological characteristics of women carrying or notBRCA1 /2 mutation, patients withBRCA mutation tend to develop early breast cancer with high-grade and triple negative tumors. However, further large scale research including more data is needed to better characterizeBRCA1 /2 cases and to evaluate the survival rate associated with these mutations in our population tumors. Moreover, it would be more interesting to study women withBRCA1 andBRCA2 mutations separately in order to determine if they exhibit distinct characteristics.